A 6-week double-blind placebo-controlled randomized multicenter study to explore the efficacy and safety of AFQ056 when combined with increased doses of L-dopa in Parkinson
Study on the Effects of an Investigational Drug for Hypertension
Not Recruiting
30 years - 80 years
All
Phase
N/A
1 Location
Brief description of study.
No Description Available
Detailed description of study
No Description Available
Eligibility of study
You may be eligible for this study if you meet the following criteria:
Conditions:Parkinson's Disease
Age:
30 years - 80 years
Gender: All
Who can participate: Adults aged 18 to 65 with a diagnosis of hypertension may be eligible to participate. Key eligibility criteria include stable medication use for at least three months and no history of cardiovascular events in the past year.
Study details: Participants will be randomly assigned to receive either the investigational drug or a placebo. They will need to take the assigned medication daily and attend regular clinic visits for monitoring and assessment.
Updated on
19 Feb 2024.
Study ID: 1105005541 (1003-14)
Interested in the study?
Select a study center that’s convenient for you, and get in touch with the study team.
